Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceHBIO -2.79%48 EV-to-FCF is 49.78 as of Jul. 14, 2026, which is 94% above its 10-year median of 25.68. GuruFocus rates HBIO with a GF Score™ of 48/100 and a GF Value™ of $19.43 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 77.29% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Harvard Bioscience's Enterprise Value is $63.77 Mil.
Harvard Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $1.28 Mil. Therefore, Harvard Bioscience's EV-to-FCF for today is 49.78.
The historical rank and industry rank for Harvard Bioscience's EV-to-FCF or its related term are showing as below:
HBIO'
s EV-to-FCF Range Over the Past 10 Years
Min: -4055.03 Med: 25.68 Max: 1414.11
Current: 49.78
During the past 13 years, the highest EV-to-FCF of Harvard Bioscience was 1414.11. The lowest was -4055.03. And the median was 25.68.
HBIO's EV-to-FCF is ranked worse than 77.29% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.445
vs HBIO: 49.78
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Harvard Bioscience's PE Ratio (TTM) for today is calculated as:
Harvard Bioscience's share price for today is $5.91.
Harvard Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Harvard Bioscience EV-to-FCF Related Terms
Harvard Bioscience EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's EV-to-FCF falls into.
Harvard Bioscience's current Enterprise Value is $63.77 Mil.
Harvard Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (HBIO) has a EV-to-FCF of 49.78 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Harvard Bioscience and its competitors. This is 94% above median its historical median of 25.68. According to the industry distribution chart, Harvard Bioscience ranks #320 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 77.3%.
Is Harvard Bioscience's EV-to-FCF too high?
Harvard Bioscience's current EV-to-FCF of 49.78 is 94% above median its 10-year median of 25.68. The Medical Devices & Instruments industry median EV-to-FCF is 23.45. Harvard Bioscience's value of 49.78 is 112.3% above this industry median. Based on the distribution chart, Harvard Bioscience ranks #320 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Harvard Bioscience has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's EV-to-FCF compare to RGNT and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #320 out of 414 companies for EV-to-FCF. This places Harvard Bioscience in the lower half of its industry. The industry median EV-to-FCF is 23.45. Harvard Bioscience's value of 49.78 is 112.3% above this benchmark. While the company's 10-year median is 25.68 vs. the industry median of 23.45, Harvard Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.45, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current EV-to-FCF of 49.78 is 112.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current EV-to-FCF is 49.78, which is 94% above median its own 10-year median of 25.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Harvard Bioscience (HBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $19.43, compared to a current price of $5.91 — trading 69.6% below its estimated fair value. The current EV-to-FCF is 49.78, which is 94% above median its 10-year median of 25.68 and 112.3% above the Medical Devices & Instruments industry median of 23.45. Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Harvard Bioscience (HBIO), the current EV-to-FCF is 49.78 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (HBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of $5.91 is trading 69.6% below its estimated GF Value™ of $19.43.
GuruFocus considers Harvard Bioscience to be Possible Value Trap.
Key valuation signals for HBIO:
EV-to-FCF: 49.78 (94% above median its 10-year median of 25.68)
GF Value™: $19.43 vs. price of $5.91 (69.6% below fair value)
Industry Position: 112.3% above the Medical Devices & Instruments median (#320 of 414)
No single metric tells the full story. See the HBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score
Get the complete analysis for HBIO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBIO has been successfully added to your 
